Abeona Therapeutics Inc. (NASDAQ:ABEO) Investor Alert: Investigation over Potential Wrongdoing
An investigation on behalf of investors in Abeona Therapeutics Inc. (NASDAQ:ABEO) shares over potential wrongdoing at Abeona Therapeutics Inc. was announced.
San Diego, CA -- (SBWire) -- 04/08/2021 --An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Abeona Therapeutics Inc.
Investors who purchased shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) and currently hold any of those NASDAQ: ABEO shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Abeona Therapeutics Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
New York based Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops cell and gene therapies for life-threatening rare genetic diseases.
Shares of Abeona Therapeutics Inc. (NASDAQ: ABEO) declined from $21.45 per share in May 2018 to as low as $0.99 per share on November 3, 2020.
Those who purchased shares of Abeona Therapeutics Inc. (NASDAQ: ABEO), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Media Relations Contact
View this press release online at: http://rwire.com/1334687